Your browser of choice has not been tested for use with If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More

Chromadex Corp CS (CDXC)

Chromadex Corp CS (CDXC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.


See More
  • Market Capitalization, $K 198,355
  • Shares Outstanding, K 59,566
  • Annual Sales, $ 31,560 K
  • Annual Income, $ -33,320 K
  • 60-Month Beta 1.38
  • Price/Sales 6.40
  • Price/Cash Flow N/A
  • Price/Book 12.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.12
  • Number of Estimates 3
  • High Estimate -0.11
  • Low Estimate -0.12
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
2.82 +18.09%
on 10/10/19
4.29 -22.38%
on 09/19/19
-0.87 (-20.71%)
since 09/18/19
2.82 +18.09%
on 10/10/19
4.88 -31.76%
on 07/30/19
-1.14 (-25.50%)
since 07/18/19
2.79 +19.35%
on 12/11/18
4.95 -32.73%
on 05/10/19
-0.36 (-9.76%)
since 10/18/18

Most Recent Stories

More News
New Study Demonstrates a Unique Role of Nicotinamide Riboside Over Other NAD Precursors

ChromaDex Corp. (NASDAQ:CDXC) announced today that the results of a preclinical study conducted by Nestle were published last month in the journal Nature Communications, a peer-reviewed open access scientific...

CDXC : 3.33 (unch)
ChromaDex Statement Regarding the October 9th Order in the Central District of California Litigation

ChromaDex Corp. (NASDAQ:CDXC) issued the following statement.

CDXC : 3.33 (unch)
Humanitarian Grant Awarded for Preclinical Study on the Impact of NAD Precursor Vitamins on Milk Bioactive Production and Brain Development in Rodents

Dr. Charles Brenner, the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa, receives a research grant from the Bill & Melinda Gates Foundation to study the effects of NAD-boosting...

CDXC : 3.33 (unch)
ChromaDex to Present at the 5th Annual B. Riley FBR Consumer and Media Conference

ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 5 Annual B. Riley FBR Consumer and Media Conference...

CDXC : 3.33 (unch)
ChromaDex Announces $7 Million Private Placement of Common Stock

ChromaDex Corp. (NASDAQ:CDXC) announced today that it has entered into a securities purchase agreement for the sale of $7.0 million of its common stock in a private placement. The private placement was...

CDXC : 3.33 (unch)
ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates

ChromaDex (CDXC) delivered earnings and revenue surprises of 15.38% and 2.74%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

CDXC : 3.33 (unch)
ChromaDex Receives Positive Opinion on Nicotinamide Riboside as a Novel Food from the World-Leading European Food Safety Authority (EFSA)

ChromaDex Corp. (NASDAQ:CDXC) today announced that the European Food Safety Authority (EFSA) has issued a positive opinion on Nicotinamide Riboside (NR) as a novel food ingredient for use in a food supplement...

CDXC : 3.33 (unch)
ChromaDex Corporation Reports Second Quarter 2019 Financial Results

Second Quarter 2019 Highlights vs. Second Quarter 2018

CDXC : 3.33 (unch)
ChromaDex Adds Top Talent to its Leadership Team

ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today three strategic hires to its executive team.

CDXC : 3.33 (unch)
ChromaDex to Report Second Quarter 2019 Financial Results on Wednesday, August 7, 2019

ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., August 7, 2019 at 4:30 p.m. Eastern time to discuss its financial results for the second quarter ended June 30, 2019....

CDXC : 3.33 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong.

See More Share

Trade CDXC with:

Business Summary

ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is...

See More

Key Turning Points

2nd Resistance Point 3.43
1st Resistance Point 3.38
Last Price 3.33
1st Support Level 3.28
2nd Support Level 3.23

See More

52-Week High 4.95
Fibonacci 61.8% 4.12
Fibonacci 50% 3.87
Fibonacci 38.2% 3.62
Last Price 3.33
52-Week Low 2.79

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar